Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,711
archived clinical trials in
Depression

A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated:  1/25/2016
Biomedical Systems, Inc
mi
from
St. Louis, MO
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated: 1/25/2016
Biomedical Systems, Inc
mi
from
St. Louis, MO
Click here to add this to my saved trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated:  1/25/2016
Biomedical Systems, Inc
mi
from
St. Louis, MO
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated: 1/25/2016
Biomedical Systems, Inc
mi
from
St. Louis, MO
Click here to add this to my saved trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated:  1/25/2016
Center for Psychiatry and Behavioral Medicine, Incorporated
mi
from
Las Vegas, NV
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated: 1/25/2016
Center for Psychiatry and Behavioral Medicine, Incorporated
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated:  1/25/2016
North Star Medical Research, LLC
mi
from
Middleburg Heights, OH
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated: 1/25/2016
North Star Medical Research, LLC
mi
from
Middleburg Heights, OH
Click here to add this to my saved trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated:  1/25/2016
IPS Research Company
mi
from
Oklahoma City, OK
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated: 1/25/2016
IPS Research Company
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated:  1/25/2016
Summit Research Network (Oregon), Incorporated
mi
from
Portland, OR
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated: 1/25/2016
Summit Research Network (Oregon), Incorporated
mi
from
Portland, OR
Click here to add this to my saved trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated:  1/25/2016
Focus and Balance, LLC
mi
from
San Antonio, TX
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated: 1/25/2016
Focus and Balance, LLC
mi
from
San Antonio, TX
Click here to add this to my saved trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated:  1/25/2016
Grayline Clinical Drug Trials
mi
from
Witchita Falls, TX
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated: 1/25/2016
Grayline Clinical Drug Trials
mi
from
Witchita Falls, TX
Click here to add this to my saved trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated:  1/25/2016
Northwest Clinical Research Center
mi
from
Bellevue, WA
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated: 1/25/2016
Northwest Clinical Research Center
mi
from
Bellevue, WA
Click here to add this to my saved trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated:  1/25/2016
Summit Research Network (Seattle) LLC
mi
from
Seattle, WA
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated: 1/25/2016
Summit Research Network (Seattle) LLC
mi
from
Seattle, WA
Click here to add this to my saved trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated:  1/25/2016
Rogers Center for Research and Training, Incorporated
mi
from
Milwaukee, WI
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated: 1/25/2016
Rogers Center for Research and Training, Incorporated
mi
from
Milwaukee, WI
Click here to add this to my saved trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated:  1/25/2016
Clinical Neuroscience Solutions, Inc
mi
from
Orlando, FL
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated: 1/25/2016
Clinical Neuroscience Solutions, Inc
mi
from
Orlando, FL
Click here to add this to my saved trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated:  1/25/2016
Cutting Edge Research Group
mi
from
Oklahoma City, OK
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated: 1/25/2016
Cutting Edge Research Group
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated:  1/25/2016
Paradigm Research Professionals, Llc
mi
from
Oklahoma City, OK
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated: 1/25/2016
Paradigm Research Professionals, Llc
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated:  1/25/2016
Clinical NeuroScience Solutions, Inc.
mi
from
Memphis, TN
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated: 1/25/2016
Clinical NeuroScience Solutions, Inc.
mi
from
Memphis, TN
Click here to add this to my saved trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated:  1/25/2016
Hospital Aranda de la Parra, S.A. de C.V.
mi
from
Leon,
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
Status: Enrolling
Updated: 1/25/2016
Hospital Aranda de la Parra, S.A. de C.V.
mi
from
Leon,
Click here to add this to my saved trials
A Study of Ketamine in Patients With Treatment-resistant Depression
A Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose Frequency Study of Ketamine in Subjects With Treatment-resistant Depression
Status: Enrolling
Updated:  1/25/2016
Clinical Research Facility
mi
from
Birmingham, AL
A Study of Ketamine in Patients With Treatment-resistant Depression
A Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose Frequency Study of Ketamine in Subjects With Treatment-resistant Depression
Status: Enrolling
Updated: 1/25/2016
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study of Ketamine in Patients With Treatment-resistant Depression
A Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose Frequency Study of Ketamine in Subjects With Treatment-resistant Depression
Status: Enrolling
Updated:  1/25/2016
Clinical Research Facility
mi
from
New York, NY
A Study of Ketamine in Patients With Treatment-resistant Depression
A Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose Frequency Study of Ketamine in Subjects With Treatment-resistant Depression
Status: Enrolling
Updated: 1/25/2016
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Ketamine in Patients With Treatment-resistant Depression
A Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose Frequency Study of Ketamine in Subjects With Treatment-resistant Depression
Status: Enrolling
Updated:  1/25/2016
Clinical Research Facility
mi
from
Charleston, SC
A Study of Ketamine in Patients With Treatment-resistant Depression
A Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose Frequency Study of Ketamine in Subjects With Treatment-resistant Depression
Status: Enrolling
Updated: 1/25/2016
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
A Study of Ketamine in Patients With Treatment-resistant Depression
A Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose Frequency Study of Ketamine in Subjects With Treatment-resistant Depression
Status: Enrolling
Updated:  1/25/2016
Clinical Research Facility
mi
from
Dallas, TX
A Study of Ketamine in Patients With Treatment-resistant Depression
A Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose Frequency Study of Ketamine in Subjects With Treatment-resistant Depression
Status: Enrolling
Updated: 1/25/2016
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of Ketamine in Patients With Treatment-resistant Depression
A Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose Frequency Study of Ketamine in Subjects With Treatment-resistant Depression
Status: Enrolling
Updated:  1/25/2016
Clinical Research Facility
mi
from
Salt Lake City, UT
A Study of Ketamine in Patients With Treatment-resistant Depression
A Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose Frequency Study of Ketamine in Subjects With Treatment-resistant Depression
Status: Enrolling
Updated: 1/25/2016
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study of Ketamine in Patients With Treatment-resistant Depression
A Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose Frequency Study of Ketamine in Subjects With Treatment-resistant Depression
Status: Enrolling
Updated:  1/25/2016
Clinical Research Facility
mi
from
Little Rock, AR
A Study of Ketamine in Patients With Treatment-resistant Depression
A Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose Frequency Study of Ketamine in Subjects With Treatment-resistant Depression
Status: Enrolling
Updated: 1/25/2016
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
A Study of Ketamine in Patients With Treatment-resistant Depression
A Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose Frequency Study of Ketamine in Subjects With Treatment-resistant Depression
Status: Enrolling
Updated:  1/25/2016
Clinical Research Facility
mi
from
Centennial, CO
A Study of Ketamine in Patients With Treatment-resistant Depression
A Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose Frequency Study of Ketamine in Subjects With Treatment-resistant Depression
Status: Enrolling
Updated: 1/25/2016
Clinical Research Facility
mi
from
Centennial, CO
Click here to add this to my saved trials
A Study of Ketamine in Patients With Treatment-resistant Depression
A Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose Frequency Study of Ketamine in Subjects With Treatment-resistant Depression
Status: Enrolling
Updated:  1/25/2016
Clinical Research Facility
mi
from
Hartford, CT
A Study of Ketamine in Patients With Treatment-resistant Depression
A Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose Frequency Study of Ketamine in Subjects With Treatment-resistant Depression
Status: Enrolling
Updated: 1/25/2016
Clinical Research Facility
mi
from
Hartford, CT
Click here to add this to my saved trials
A Study of Ketamine in Patients With Treatment-resistant Depression
A Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose Frequency Study of Ketamine in Subjects With Treatment-resistant Depression
Status: Enrolling
Updated:  1/25/2016
Clinical Research Facility
mi
from
New Haven, CT
A Study of Ketamine in Patients With Treatment-resistant Depression
A Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose Frequency Study of Ketamine in Subjects With Treatment-resistant Depression
Status: Enrolling
Updated: 1/25/2016
Clinical Research Facility
mi
from
New Haven, CT
Click here to add this to my saved trials
A Study of Ketamine in Patients With Treatment-resistant Depression
A Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose Frequency Study of Ketamine in Subjects With Treatment-resistant Depression
Status: Enrolling
Updated:  1/25/2016
Clinical Research Facility
mi
from
Atlanta, GA
A Study of Ketamine in Patients With Treatment-resistant Depression
A Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose Frequency Study of Ketamine in Subjects With Treatment-resistant Depression
Status: Enrolling
Updated: 1/25/2016
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of Ketamine in Patients With Treatment-resistant Depression
A Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose Frequency Study of Ketamine in Subjects With Treatment-resistant Depression
Status: Enrolling
Updated:  1/25/2016
Clinical Research Facility
mi
from
Rockville, MD
A Study of Ketamine in Patients With Treatment-resistant Depression
A Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose Frequency Study of Ketamine in Subjects With Treatment-resistant Depression
Status: Enrolling
Updated: 1/25/2016
Clinical Research Facility
mi
from
Rockville, MD
Click here to add this to my saved trials
A Study of Ketamine in Patients With Treatment-resistant Depression
A Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose Frequency Study of Ketamine in Subjects With Treatment-resistant Depression
Status: Enrolling
Updated:  1/25/2016
Clinical Research Facility
mi
from
Marlton, NJ
A Study of Ketamine in Patients With Treatment-resistant Depression
A Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose Frequency Study of Ketamine in Subjects With Treatment-resistant Depression
Status: Enrolling
Updated: 1/25/2016
Clinical Research Facility
mi
from
Marlton, NJ
Click here to add this to my saved trials
A Study of Ketamine in Patients With Treatment-resistant Depression
A Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose Frequency Study of Ketamine in Subjects With Treatment-resistant Depression
Status: Enrolling
Updated:  1/25/2016
Clinical Research Facility
mi
from
Allentown, PA
A Study of Ketamine in Patients With Treatment-resistant Depression
A Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose Frequency Study of Ketamine in Subjects With Treatment-resistant Depression
Status: Enrolling
Updated: 1/25/2016
Clinical Research Facility
mi
from
Allentown, PA
Click here to add this to my saved trials
Adjunctive Brief Behavioral Treatment of Insomnia (BBTI) for Sleep Intervention (SI)
An Adjunctive Behavioral Sleep Intervention to Prevent Veteran Suicides
Status: Enrolling
Updated:  1/25/2016
Syracuse VA Medical Center, Syracuse, NY
mi
from
Syracuse, NY
Adjunctive Brief Behavioral Treatment of Insomnia (BBTI) for Sleep Intervention (SI)
An Adjunctive Behavioral Sleep Intervention to Prevent Veteran Suicides
Status: Enrolling
Updated: 1/25/2016
Syracuse VA Medical Center, Syracuse, NY
mi
from
Syracuse, NY
Click here to add this to my saved trials
Behavioral Therapy Development for Methamphetamine Abuse
Behavioral Therapy Development for Methamphetamine Abuse
Status: Enrolling
Updated:  1/26/2016
UCLA Center for Clinical AIDS Research and Education (CARE) Clinic
mi
from
Los Angeles, CA
Behavioral Therapy Development for Methamphetamine Abuse
Behavioral Therapy Development for Methamphetamine Abuse
Status: Enrolling
Updated: 1/26/2016
UCLA Center for Clinical AIDS Research and Education (CARE) Clinic
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Detecting Post-Operative Respiratory Depression in Children
Detecting Post-Operative Respiratory Depression in Children: Are Our Current Standards Good Enough?
Status: Enrolling
Updated:  1/26/2016
Yale-New Haven Children's Hospital
mi
from
New Haven, CT
Detecting Post-Operative Respiratory Depression in Children
Detecting Post-Operative Respiratory Depression in Children: Are Our Current Standards Good Enough?
Status: Enrolling
Updated: 1/26/2016
Yale-New Haven Children's Hospital
mi
from
New Haven, CT
Click here to add this to my saved trials
Beating the Blues for Your Heart
Computer-Based Depression Treatment to Reduce Coronary Artery Disease Risk
Status: Enrolling
Updated:  1/27/2016
Indiana University-Purdue University Indianapolis (IUPUI)
mi
from
Indianapolis, IN
Beating the Blues for Your Heart
Computer-Based Depression Treatment to Reduce Coronary Artery Disease Risk
Status: Enrolling
Updated: 1/27/2016
Indiana University-Purdue University Indianapolis (IUPUI)
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Targeted Self-Management for Epilepsy and Serious Mental Illness (TIME)
Targeted Self-Management for Epilepsy and Serious Mental Illness
Status: Enrolling
Updated:  1/27/2016
University Hospitals at Case Medical Center
mi
from
Cleveland, OH
Targeted Self-Management for Epilepsy and Serious Mental Illness (TIME)
Targeted Self-Management for Epilepsy and Serious Mental Illness
Status: Enrolling
Updated: 1/27/2016
University Hospitals at Case Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Psychotherapy for Depressed Mothers of Psychiatrically Ill Children
Psychotherapy for Depressed Mothers of Psychiatrically Ill
Status: Enrolling
Updated:  1/28/2016
Western Psychiatric Institute and Clinic
mi
from
Pittsburgh, PA
Psychotherapy for Depressed Mothers of Psychiatrically Ill Children
Psychotherapy for Depressed Mothers of Psychiatrically Ill
Status: Enrolling
Updated: 1/28/2016
Western Psychiatric Institute and Clinic
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Development of an Insomnia Treatment for Depressed Adolescents
Development of an Insomnia Treatment for Depressed Adolescents
Status: Enrolling
Updated:  1/28/2016
University of Michigan
mi
from
Ann Arbor, MI
Development of an Insomnia Treatment for Depressed Adolescents
Development of an Insomnia Treatment for Depressed Adolescents
Status: Enrolling
Updated: 1/28/2016
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder
An Open-label Study Evaluating the Pharmacokinetics and Tolerability of [Vortioxetine] Lu AA21004 in Connection With Multiple Oral Dosing of [Vortioxetine] Lu AA21004 in Child and Adolescent Patients With a DSM-IV Diagnosis of Depressive or Anxiety Disorder
Status: Enrolling
Updated:  1/29/2016
US001
mi
from
Cleveland, OH
Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder
An Open-label Study Evaluating the Pharmacokinetics and Tolerability of [Vortioxetine] Lu AA21004 in Connection With Multiple Oral Dosing of [Vortioxetine] Lu AA21004 in Child and Adolescent Patients With a DSM-IV Diagnosis of Depressive or Anxiety Disorder
Status: Enrolling
Updated: 1/29/2016
US001
mi
from
Cleveland, OH
Click here to add this to my saved trials
Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder
An Open-label Study Evaluating the Pharmacokinetics and Tolerability of [Vortioxetine] Lu AA21004 in Connection With Multiple Oral Dosing of [Vortioxetine] Lu AA21004 in Child and Adolescent Patients With a DSM-IV Diagnosis of Depressive or Anxiety Disorder
Status: Enrolling
Updated:  1/29/2016
US002
mi
from
Cincinnatti, OH
Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder
An Open-label Study Evaluating the Pharmacokinetics and Tolerability of [Vortioxetine] Lu AA21004 in Connection With Multiple Oral Dosing of [Vortioxetine] Lu AA21004 in Child and Adolescent Patients With a DSM-IV Diagnosis of Depressive or Anxiety Disorder
Status: Enrolling
Updated: 1/29/2016
US002
mi
from
Cincinnatti, OH
Click here to add this to my saved trials
Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder
An Open-label Study Evaluating the Pharmacokinetics and Tolerability of [Vortioxetine] Lu AA21004 in Connection With Multiple Oral Dosing of [Vortioxetine] Lu AA21004 in Child and Adolescent Patients With a DSM-IV Diagnosis of Depressive or Anxiety Disorder
Status: Enrolling
Updated:  1/29/2016
US003
mi
from
Washington,
Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder
An Open-label Study Evaluating the Pharmacokinetics and Tolerability of [Vortioxetine] Lu AA21004 in Connection With Multiple Oral Dosing of [Vortioxetine] Lu AA21004 in Child and Adolescent Patients With a DSM-IV Diagnosis of Depressive or Anxiety Disorder
Status: Enrolling
Updated: 1/29/2016
US003
mi
from
Washington,
Click here to add this to my saved trials
Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder
An Open-label Study Evaluating the Pharmacokinetics and Tolerability of [Vortioxetine] Lu AA21004 in Connection With Multiple Oral Dosing of [Vortioxetine] Lu AA21004 in Child and Adolescent Patients With a DSM-IV Diagnosis of Depressive or Anxiety Disorder
Status: Enrolling
Updated:  1/29/2016
US004
mi
from
Wichita, KA
Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder
An Open-label Study Evaluating the Pharmacokinetics and Tolerability of [Vortioxetine] Lu AA21004 in Connection With Multiple Oral Dosing of [Vortioxetine] Lu AA21004 in Child and Adolescent Patients With a DSM-IV Diagnosis of Depressive or Anxiety Disorder
Status: Enrolling
Updated: 1/29/2016
US004
mi
from
Wichita, KA
Click here to add this to my saved trials
Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder
An Open-label Study Evaluating the Pharmacokinetics and Tolerability of [Vortioxetine] Lu AA21004 in Connection With Multiple Oral Dosing of [Vortioxetine] Lu AA21004 in Child and Adolescent Patients With a DSM-IV Diagnosis of Depressive or Anxiety Disorder
Status: Enrolling
Updated:  1/29/2016
DE002
mi
from
Berlin,
Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder
An Open-label Study Evaluating the Pharmacokinetics and Tolerability of [Vortioxetine] Lu AA21004 in Connection With Multiple Oral Dosing of [Vortioxetine] Lu AA21004 in Child and Adolescent Patients With a DSM-IV Diagnosis of Depressive or Anxiety Disorder
Status: Enrolling
Updated: 1/29/2016
DE002
mi
from
Berlin,
Click here to add this to my saved trials
Oral Ketamine in the Treatment of Depression and Anxiety in Patients With Cancer
Oral Ketamine in the Treatment of Depression and Anxiety in Patients With Cancer
Status: Enrolling
Updated:  1/29/2016
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Oral Ketamine in the Treatment of Depression and Anxiety in Patients With Cancer
Oral Ketamine in the Treatment of Depression and Anxiety in Patients With Cancer
Status: Enrolling
Updated: 1/29/2016
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Oral Ketamine in the Treatment of Depression and Anxiety in Patients With Cancer
Oral Ketamine in the Treatment of Depression and Anxiety in Patients With Cancer
Status: Enrolling
Updated:  1/29/2016
Yuma Regional Medical Center
mi
from
Yuma, AZ
Oral Ketamine in the Treatment of Depression and Anxiety in Patients With Cancer
Oral Ketamine in the Treatment of Depression and Anxiety in Patients With Cancer
Status: Enrolling
Updated: 1/29/2016
Yuma Regional Medical Center
mi
from
Yuma, AZ
Click here to add this to my saved trials
New Technologies for Cognitive Behavior Therapy (CBT) Treatment of Adolescent Depression
New Technologies for Cognitive Behavior Therapy (CBT) Treatment of Adolescent Depression
Status: Enrolling
Updated:  2/1/2016
Center for Telepsychology / Psychological Consultation
mi
from
Madison, WI
New Technologies for Cognitive Behavior Therapy (CBT) Treatment of Adolescent Depression
New Technologies for Cognitive Behavior Therapy (CBT) Treatment of Adolescent Depression
Status: Enrolling
Updated: 2/1/2016
Center for Telepsychology / Psychological Consultation
mi
from
Madison, WI
Click here to add this to my saved trials
MR Imaging Biomarkers of Disease Response to ECT (Electroconvulsive Therapy) in Depression
MR Imaging Biomarkers of Disease Response to ECT in Depression
Status: Enrolling
Updated:  2/2/2016
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
MR Imaging Biomarkers of Disease Response to ECT (Electroconvulsive Therapy) in Depression
MR Imaging Biomarkers of Disease Response to ECT in Depression
Status: Enrolling
Updated: 2/2/2016
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Status: Enrolling
Updated:  2/2/2016
Pacific Clinical Research Medical Group
mi
from
Arcadia, CA
Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Status: Enrolling
Updated: 2/2/2016
Pacific Clinical Research Medical Group
mi
from
Arcadia, CA
Click here to add this to my saved trials
Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Status: Enrolling
Updated:  2/2/2016
Southwestern Research
mi
from
Beverly Hills, CA
Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Status: Enrolling
Updated: 2/2/2016
Southwestern Research
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Status: Enrolling
Updated:  2/2/2016
Synergy Escondido
mi
from
Escondido, CA
Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Status: Enrolling
Updated: 2/2/2016
Synergy Escondido
mi
from
Escondido, CA
Click here to add this to my saved trials
Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Status: Enrolling
Updated:  2/2/2016
Collaborative Neuroscience Network
mi
from
Garden Grove, CA
Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Status: Enrolling
Updated: 2/2/2016
Collaborative Neuroscience Network
mi
from
Garden Grove, CA
Click here to add this to my saved trials
Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Status: Enrolling
Updated:  2/2/2016
Synergy Clinical Research Center
mi
from
National City, CA
Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Status: Enrolling
Updated: 2/2/2016
Synergy Clinical Research Center
mi
from
National City, CA
Click here to add this to my saved trials